Cspc Pharmaceutical

CSPC Pharmaceutical, headquartered in HK and operating within the Pharmaceutical Preparation Manufacturing industry, is committed to reducing its environmental impact. For 2024, the company reported Scope 1 emissions of approximately 474,567,040 kg CO2e and Scope 2 emissions of approximately 493,310,000 kg CO2e. In 2023, their Scope 1 emissions were about 663,224,000 kg CO2e, and Scope 2 emissions were approximately 418,037,000 kg CO2e. Their total emissions for 2022 were approximately 1,137,042,000 kg CO2e (Scope 1 and 2), and for 2021, total emissions were approximately 1,181,000,000 kg CO2e (Scope 1 and 2). In 2020, total emissions amounted to approximately 1,047,584,000 kg CO2e (Scope 1 and 2).

CSPC Pharmaceutical has set several intensity reduction targets. They aim to reduce greenhouse gas emissions per unit of revenue by 53% by 2026 and by 60% by 2030, both based on a 2017 baseline. Further targets include a 56% reduction in emissions per unit revenue by 2028 for both Scope 1 and Scope 2. The company also plans to reference the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) to identify and manage climate-related risks and opportunities, with the goal of minimising its carbon footprint from operational activities. Scope 3 emissions data is not currently available.